Increased occurrence of malignancy before and after chemoradiation for anal squamous cell carcinoma: a multi-institutional analysis

被引:0
作者
Kumar, Ritesh [1 ]
Hallemeier, Chris L. [2 ]
Chang, Daniel T. [3 ]
Lu, Shou-En [4 ]
Hathout, Lara [1 ]
Hristidis, Vasilis C. [5 ]
Jethwa, Krishnan R. [2 ]
Baclay, J. Richelcyn M.
Manne, Veeraswamy [1 ]
Chakrani, Zakaria [5 ]
Haddock, Michael G. [2 ]
Toesca, Diego Augusto Santos [7 ]
Pollom, Erqi Liu [6 ]
Wu, Abraham J. [5 ]
Sandhyavenu, Harigopal [2 ]
Romesser, Paul B. [5 ]
Jabbour, Salma K. [1 ]
机构
[1] Rutgers Canc Inst New Jersey, Dept Radiat Oncol, 195 Little Albany St, Newark, NJ 08901 USA
[2] Mayo Clin, Dept Radiat Oncol, Rochester, NY 55905 USA
[3] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA
[4] Rutgers State Univ, Sch Publ Hlth, Dept Biostat & Epidemiol, Piscataway, NJ 08854 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA
[6] Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA
[7] Mayo Clin, Dept Radiat Oncol, Phoenix, AZ 85024 USA
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2025年
关键词
2ND PRIMARY MALIGNANCIES; HUMAN-PAPILLOMAVIRUS; CANCER; RISK; IMMUNOSUPPRESSION; SURVIVORS; THERAPY;
D O I
10.1093/jnci/djae309
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Anal squamous cell carcinoma is a rare cancer with increased occurrence of multiple cancers before and after the anal squamous cell carcinoma diagnosis. However, there are limited data on this aspect. This multi-institutional analysis aimed to define the occurrence of malignancies before and after anal squamous cell carcinoma, time trends, and impact on survival and to identify prognostic factors.Methods Initial primary malignancy was defined as a malignancy occurring before the anal squamous cell carcinoma. Second primary malignancy was defined as a distinct primary cancer that developed after anal squamous cell carcinoma diagnosis. Retrospective multi-institutional chart review was done. Progression-free survival (PFS), overall survival, and prognostic factors were evaluated.Results A total of 647 patients with anal squamous cell carcinoma treated with curative intent were analyzed. Median age was 61.2 years with 72% as females. Of these, 150 (23.3%) patients had multiple malignancies with initial primary malignancy in 16% and second primary malignancy in 8%. Patients without prior cancer had better 5-year PFS (81.2% vs 67.2%, P = .011) and overall survival (81% vs 69%, P = .008) compared with those with prior cancer. Second primary malignancies had a statistically significant adverse impact on PFS (hazard ratio [HR] = 4.22) and overall survival (HR = 3.56). Females had better 5-year PFS (82% vs 70%, P = .016) as compared with males. The median time interval for developing anal squamous cell carcinoma (as second primary malignancy) after initial primary malignancy was 9.32 years.Conclusions Anal squamous cell carcinoma patients have an increased risk of multiple malignancies. These patients who have prior cancers have inferior outcomes. Second primary malignancy is a poor prognostic factor in patients with anal cancer. Second primary malignancy can develop years after treatment of primary anal squamous cell carcinoma.
引用
收藏
页码:772 / 780
页数:9
相关论文
共 28 条
  • [1] Incidence, Risk Factors, and Mortality Associated With Second Malignant Neoplasms Among Survivors of Adolescent and Young Adult Cancer
    Chao, Chun
    Bhatia, Smita
    Xu, Lanfang
    Cannavale, Kimberly L.
    Wong, F. Lennie
    Huang, Po-Yin Samuel
    Cooper, Robert
    Armenian, Saro H.
    [J]. JAMA NETWORK OPEN, 2019, 2 (06) : e195536
  • [2] Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries
    de Gonzalez, Amy Berrington
    Curtis, Rochelle E.
    Kry, Stephen F.
    Gilbert, Ethel
    Lamart, Stephanie
    Berg, Christine D.
    Stovall, Marilyn
    Ron, Elaine
    [J]. LANCET ONCOLOGY, 2011, 12 (04) : 353 - 360
  • [3] Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta-analysis
    De Vuyst, Hugo
    Clifford, Gary M.
    Nascimento, Maria Claudia
    Madeleine, Margaret M.
    Franceschi, Silvia
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (07) : 1626 - 1636
  • [4] Risk of Second Primary Malignancies Among Cancer Survivors in the United States, 1992 Through 2008
    Donin, Nicholas
    Filson, Christopher
    Drakaki, Alexandra
    Tan, Hung-Jui
    Castillo, Alex
    Kwan, Lorna
    Litwin, Mark
    Chamie, Karim
    [J]. CANCER, 2016, 122 (19) : 3075 - 3086
  • [5] MALIGNANCIES THAT OCCUR BEFORE AND AFTER ANAL CANCER - CLUES TO THEIR ETIOLOGY
    FRISCH, M
    OLSEN, JH
    MELBYE, M
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1994, 140 (01) : 12 - 19
  • [6] Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis
    Gilbert, Duncan C.
    Wakeham, Katie
    Langley, Ruth E.
    Vale, Claire L.
    [J]. BRITISH JOURNAL OF CANCER, 2019, 120 (02) : 256 - 268
  • [7] Anal Cancer: The Past, Present and Future
    Gondal, Talha Ashraf
    Chaudhary, Noman
    Bajwa, Husnaat
    Rauf, Aribah
    Le, Duc
    Ahmed, Shahid
    [J]. CURRENT ONCOLOGY, 2023, 30 (03) : 3232 - 3250
  • [8] Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions
    Hoots, Brooke E.
    Palefsky, Joel M.
    Pimenta, Jeanne M.
    Smith, Jennifer S.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (10) : 2375 - 2383
  • [9] Risk of second tumor in intracranial germinoma patients treated with radiation therapy: the Johns Hopkins experience
    Jabbour, Salma K.
    Zhang, Zhe
    Arnold, Dagmar
    Wharam, Moody D.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2009, 91 (02) : 227 - 232
  • [10] Malignancies diagnosed before and after anal squamous cell carcinomas: A SEER registry analysis
    Jani, Krupa S.
    Lu, Shou-En
    Murphy, James D.
    Romesser, Paul B.
    Jethwa, Krishan R.
    Li, Diana
    Chundury, Anupama
    Wu, Abraham J.
    Hathout, Lara
    Hallemeier, Christopher L.
    Jabbour, Salma K.
    [J]. CANCER MEDICINE, 2021, 10 (11): : 3575 - 3583